Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It took 20 years for Penicillin to become a "greatness" drug. Sometimes events cause a lapse. Any idea to fruition has setbacks. If you minimize mistakes you gain time. Rome wasn't built in a day. When in Rome do as the Romans do. :)
L vus
I respect your wanting to hold feet to the fire. I have been a shareholder since 2008. I know the CEO reads the posts on this board. He told me that some on the board have legitimate gripes but others are only interested in objections with no merit, similar to the SA article. My take is that we are invested in a company that is on the brink of greatness and if you stand back and look objectively, you can conclude that Dr Seymour doesn't have time on his side anymore and Cides have to show up to prove their power or the stock will continue slowly eroding. I'm betting on the Cides.
L vus
Dr Seymour never said he would make an announcement today. His only comment was he would make it shortly. There are reasons for this that have to do with having no mistakes before testing commences. You can read into that what you may but Dr Seymour is serious about no mistakes. They may be sampling batches or whatever to keep quality control exact before shipping to BASi. Another event is BASi giving the go ahead to ship.
L vus
You have the NNVC plan in a nutshell . What is very special is the timing of the virus.
Once the primates are showed to be cured by EbolaCide2 then human tests will begin with the 100 million to irradiciate the ebola virus. I hope this is clear.
L vus
A lot of big players own NNVC as has been reported here many times. 10% of the stock is held by institutional investors. The Baker Boys recently have started acquiring and they are as good as it gets when it comes to small biotech stocks.
L vus
Thank you sarshee, that was exactly what I was trying to convey. The U.S. GOV'T knows this full well and this maybe one way they ( ISIS ) are planing to attack us. NNVC might become a household word.
L vus
Nano, you know a lot more and aren't saying and I know why. I respect your silence.
The US allows for this under the" Breakthrough Drug Act" as I understood Dr Seymour to say.
I wish you were right JG, but this is far, far from being over left unchecked as it is now. There is a possibility that a mutation is occuring that will make ebola airborne. Also the United States was almost exposed to a passenger headed for New York, but he became sick and was not allowed to board thank God as he had the virus.
Anyone who doesn't take ebola seriously is not thinking correctly. Isis could infect one of its American passport carrying crazies to return to the U.S. and kiss and shake hands with as many people as he could.He could move over a lot of territory. This is scary
L vus
Let me say something that I put out of context. The 1 billion market cap was from a question from the audience stating that the market cap of NNVC was about 200 million and what would it take for it to get to 1 billion. He asked for any stockholders in the audience to answer that question. I raised my hand and said the successful completion of tox. Dr Seymour said that would affect the sp a little but ebola would move the market cap to at least a billion.
L vus
Sorry for not getting in touch sooner. I feel like Moses coming down from Mt. Sinai.
The luncheon in Aspen was a full house to hear Dr Seymour. There were quite a few physicians
attending asking all about Ebola.
One question was asked about vaccine vs EbolaCide 2. The direct answer was that no vaccine would work completely because of the constant mutation of the virus. Dr Seymour said that the latest figures show over 400 mutations since the outbreak started according to Harvard. He is confident in EbolaCide 2 because of the ebola cellular receptor NPC1 being successfully mimicked and avoiding the decoys of the ebola virus.
Dr Seymour is departing shortly for Africa over the objections of his family. He has been asked by the President of an African country, Rwanda I believe, to meet and discuss treating small primates and lowland gorillas in the wild. This would be accomplished by using a specially designed dart gun to inject the animals. Most people are unaware of primates dying from ebola and if left unchecked a possible extinction. Furthermore the silverbacks could become infected and meet a similar fate.
After EbolaCide2 has been proven in the wild, Dr Seymour will ask the Govt. for 100 million to get the human program started. The" Breakthrough Drug Act" allows for this.
About tox, Dr Seymour and I had a short discussion after his presentation and he said all the material has been made to ship to Basi and he is going to announce the commencement of tox testing very shortly.
About plant production quantities, that is the responsibility of the production managers who deal with
that day to day. Dr Seymour has no hard numbers to respond to.
Another announcement Dr Seymour made was about Oral Flucide. The production would be handled by a plant in Texas. This will occur after injectables are established.
According to Dr Seymour, the market cap for NNVC when EbolaCide 2 is proven will be 1 billion. This is coming soon.
L vus
JG, you and I are together on this and my plan is to eat lunch then question Dr Seymour. If I get the opportunity before the luncheon, I will get some answers in the most polite way for a stockholder of 6 years to act.
GO NNVC!
You had two that JG36 didn't , quantity required and PHE and MERS, what happened?
Thanks DS,
L vus
JG36 has given me excellent questions for tomorrow's luncheon with Dr Seymour in Aspen. I would ask if anyone in our group has questions to please send them to me so I can communicate them to Dr Seymour.
Thank you all,
L vus
We all want to know the answers to those questions. I would be smart to eat my lunch before any questions.
I will attend the luncheon in Aspen on wed. the 17th. Thanks for the heads up leif. Any questions for the good Dr. ? HAHAHA
You say what you want. It will come to pass. The world needs cides. Maybe you will need cides someday and will see its value. Before the end of the year we will see.
NanoViricides holds the science to defeat virus. Ebola will be defeated by NNVC. When it becomes evident as to what NanoViricides has, the pps will be of a magnitude not seen on the stock exchange. I am so excited about what is going to happen when NNVC is given the chance. GLTA
Thanks for the answer. i was thinking that B-OM might clear up the tissue of the inflamed esophagus before the mutated cells became cancer.
BK, Barrett's esophagus has a predisposition to esopageal adenocarcinoma. It would be great if B-OM could be a treatment to keep the esophagus from becoming cancerous.Maybe some type of throat swab could be used? Your opinion is always valued.
I was going to post this yesterday but yesterdays gone, from Patrick Cox: NanoViricides Changes Course on Ebola
Dear TransTech Reader,
NanoViricides’ (NNVC) leadership has decided that the magnitude of the Ebola outbreak warrants at least preliminary development of an Ebola drug. In the early stages of the current Ebola epidemic, Dr. Eugene Seymour was committed to ignoring the disease. Since then, however, the disease has spread far beyond all early projections.
On Tuesday, the company issued a statement and announced at the Rodman and Renshaw Conference in New York that an anti-Ebola broad-spectrum drug had been designed and is currently being synthesized. Seymour has assured me, however, that this effort will not slow down development of the company’s lead drug candidate for influenza.
The calculations behind this decision are extremely interesting. As I’ve pointed out before, an Ebola drug is never going to make anybody significant revenues compared to the kind of money that would come from an influenza drug. In terms of the company’s long-term value, influenza is clearly the right path.
Because the flu is so easily spread, it can reach every part of the world. As a result, the potential patient population for an influenza drug is virtually every human on the planet. The first iteration of FluCide would be an injectable that would be sold primarily to medical personnel who are most at risk of contracting influenza during an outbreak. I’ve pointed out that the British healthcare system allows sales of unapproved drugs, and it is certainly within the realm of possibility that FluCide would be used first by Brit hospital workers. I expect that the company would net many thousands of dollars per dose.
The next target market would be hospitalized influenza victims. Increasingly, American hospitals are paid fixed amounts per influenza victims, so a drug that could end symptoms within hours, which is what we expect based on animal models, would save hospitals significant amounts even if doses were priced in the thousands of dollars.
As you will recall, however, the company has already shown that it can make an oral version of the flu drug. This would expand the market for FluCide by many orders of magnitude. I know people who carry the largely ineffective Tamiflu—just in case. Once NanoViricides’ clinical trials of an oral flu drug show real efficacy, it could easily break drug sales records as people buy it in preparation for a possible infection. Hundreds of millions of doses is probably a conservative estimation of annual sales. Even if the cost were only a few hundred dollars, revenues would be enormous.
So why is the company looking at Ebola? I believe it is because a successful drug for this deadly disease would end speculation about this new nanobiotechnology. We’ve seen other companies’ stock prices skyrocket on the slimmest of news regarding Ebola drugs, and those drugs are mostly hard-to-manufacture and expensive biologics. NanoViricides’ drug platform is the opposite, inexpensive and easy to manufacture.
Think of nanoviricides as a big Lego kit made up of many different polymer nanomicelles and ligands. The nanomicelles are roughly spherical artificial cells. The ligands are the active segments of the signaling molecules that viruses home in on when they are searching for the type of cell they evolved to infect. When viruses attach to those ligands, it sends an electrochemical signal to the nanomicelle, causing it to open and welcome the virus to its doom.
At this point, NanoViricides’ president, Dr. Anil Diwan, has developed a huge library of nanomicelles and ligands that can be quickly assembled and tested against viruses. It takes little time or money to work out the most likely combinations and test them for efficacy.
Ebola, however, is an extremely complex virus that does not limit itself to some basic cell type. In the past, the company failed to find a solution to this problem. Since then, however, much has been learned about the virus and, based on this information, Diwan believes he can construct a nanoviricide that will be effective against Ebola.
If he’s right, the benefit to the company would be instant credibility, which would almost certainly increase stock prices. Moreover, the current hysteria about the disease virtually guarantees that funding would appear to finance an Ebola program. This is why, incidentally, such an effort could be undertaken without threatening the company’s future revenue streams, the true long-term basis of a company’s value.
Success would also accelerate the process of acquiring funds to launch programs against other easier viruses, including herpes and perhaps even HIV. Because the technology’s R&D is mostly accomplished, several viruses that have recently appeared in America could also be addressed in short order. This includes dengue and the extraordinarily painful Chikungunya virus, sometimes called break bone disease because that’s what it feels like. The enterovirus D68 is also straining hospital capacities in some areas. I believe, by the way, that you would do more in the long run to win the fight against virus-borne diseases by investing in NanoViricides than giving t o any charity.
There is another factor, however, that may be motivating the company to take a chance with Ebola. It may be personal. As you know, NanoViricides was the subject, some months ago, of what appeared to be a concerted, dishonest manipulation. The company is aggressively pursuing legal action against the financial website that published an anonymous and clearly inaccurate attack on the company. If, by the way, the lawsuit is successful in forcing this website to reveal the identity of those involved in the attack, it could have enormous and welcome consequences that would affect many financial websites who host such attacks.
There is still a relatively large overhang of short positions on NanoViricides. A successful test of an Ebola drug could increase the stock price to the point that shorters would have to scramble to cover their positions, resulting in a classic short squeeze.
When I look at the decision to tackle Ebola, it seems like an unnecessary distraction and risk, but that’s exactly the reason that I believe the famously cautious Diwan must know what he’s doing. I just don’t believe that he would place this bet if he did not believe that he’s got a pretty darn sure thing. I’m minded, in fact, of a great song by one of my favorite contemporary bands, Elbow. Only time will tell, of course, but I just thought you’d like to know.
You can read the entire press release here. I’ll have a video interview with CEO Dr. Eugene Seymour, in which we discuss this topic, in the next few weeks.
For transformational profits,
Patrick Cox
Reply, Reply All or Forward | More
Click to reply all
Send
Discover something new.
daBoze, as much as I believe in the science, I am in agreement. What is the holdup?
leifsmith, that was brilliantly stated. I would add that NNVC is adept at three card monty and that has some of our posters entranced. If they're not careful they will lose their shirts.
Steady T, you are right but we can do both.
Thank you for an informing post.zMapp was able to be first and yet other than exposure the treatment is inconclusive.
Bullshit, posts that attack NNVC management are groundless and absurd.
Done, and I would urge everyone to support this.
Amen,to not try is unethical.
Are you better at biotech investing than the Baker Brothers?
Your grandson is so lucky to have a loving grand dad. Baker Bros. is awesome. I have pretty much invested along similar stocks and want you to succeed too. From one grand dad to another, we gotta help with the tuition. Go ct.x and nnvc .
Congrats, he looks just like you. Save me one of your cigars for Hawaii. What will he call you?
That's your best post. I might have to unblock you, literally!
This was an email to me from Dr Harris:
Jul 1, 2013
Dear Bob
all the data regarding our testing of the dengue Nanoviricides was given to the company, and they have published press releases, etc. Our agreement is that we deliver the data to them and they release it in whatever format is appropriate…. Yes, we are excited they have filed for orphan drug status and are planning to continue our work with them again.
best
Eva
I thought it was very encouraging.
L vus
Go NNVC forever. When food is scarce I skin a rabbit and throw him in the pot.
You are so right. They sang Mondray, Mondray and Calaphrama Dreaming. Phrama Cass choked on a sandwich before anyone knew the phramlick maneuver.
You're a good soul, larson1. I am looking forward to meeting y'all in Hawaii. I have never sold one share and am respectful of the science that will garner a Nobel Prize. Maybe we should go to Stockholm and bask in NNVC's award as long time stockholders. GO NNVC!!!!!!!
Go NNVC!!!!!!!!!!!!!
I am so happy that these thugs are ignored.They have such low self esteem that they will say or do anything. They are simply thugs, nothing less, nothing more. To pay attention and give them an important opportunity to them to spill their trite is nonsense. They are leaches and will drop off before too long. Scum is scum. Go NNVC we will overcome. I don't like cowards who act like they are intelligent. Other than that I could care less. GOOOO NNVC!!!!
Celgene hasn't got the resources, meaning cash and stock that is needed for a deal for Ctix Kevetrin not including all other testing compounds. Awhile back Leo said Kevetrin by itself was worth 30 -50 billion after phase 2. No other big pharma has the cash to make Leo say YES. This is why my money is with CTIX and DR Erlich.
Weedie, my wife and I rescued a Jack Russell from the Animal Shelter for 50 dollars. She is so loving and only 4 mo old as best as the vet can tell, teeth and bone structure. I will never go back as it broke my heart to hear the yelping. I wanted to take them all out of there. GO NNVC and long live" JOY" our rescue dog.